Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy

Area of Science:

• Ophthalmology
• Pharmacology

Background:

• Phosphodiesterase-5 inhibitors (PDE5I) are widely used for erectile dysfunction and pulmonary arterial hypertension.
• PDE5I have been suggested as a potential cause of nonarteritic anterior ischemic optic neuropathy (NAION).
• A definitive causal link and mechanism between PDE5I use and NAION remain subjects of ongoing debate.

Purpose of the Study:

• To explore the potential relationship between PDE5 inhibitor use and the development of NAION.
• To highlight the importance of considering PDE5I as a contributing factor in NAION cases.

Main Methods:

• Review of existing literature and clinical observations regarding PDE5I and NAION.
• Clinical inquiry into patient medication history during NAION diagnosis.

Main Results:

• While a direct causal link is debated, a potential association between PDE5I and NAION is recognized.
• The precise mechanism underlying PDE5I's role in NAION is not fully elucidated.

Conclusions:

• Neuro-ophthalmologists should routinely inquire about PDE5I use in patients diagnosed with new-onset NAION.
• Patients diagnosed with NAION should be counseled on the potential implications of continued PDE5I use.